Os: Your tact and charm is showing again! 8)
Last time I checked, this was a discussion forum.
King of the oneliners I am not.
It takes me twenty just to get out of bed ;D
And we're no longer dealing with simple h2o based extractions.
So, in keeping with my x-stream wankerabiltity and proof of such....especially since you've neglected to do anything about that chronic assholism... ;) :) here is a new patent for you to chew on and digest. :P
Which....coincidently shoots holes into duplicating "Stomach Digestive Solvation" extraction possibilities being kicked around as of late.
Ya think they saw us cumming??? :-[
It incorporates pH buffering that prevents the drug form from releasing virtually any active ingredient in the stomach and enables uniform and long-lasting release of active ingredient in the intestine, in particular shortly before or only in the colonic region.
How Nifty is that...Ya???
Think Deep on this bees!
Issued October 14, 2003.(It was filed 23 months prior to approval)
Patent US6632454 (http://l2.espacenet.com/dips/viewer?PN=US6632454&CY=gb&LG=en&DB=EPD)
Notes of special interest under
Examples of Active Ingredients
New Active Ingredients and Active Ingredients Under-going Development and Testing
Literature from Relevant Pharmaceutical Databases Known to the Skilled Worker
Both of which reek of non-disclosure in light of being listed among 38 substances >:(
Abstract
The invention relates to the use of a multilayer pharmaceutical product that substantially comprises a) a core containing a pharmaceutically active substance, b) an inner coating consisting of a copolymer or a mixture of copolymers that are composed of 85 to 98 wt.- % of radically polymerized C1 to C4 alkyl esters of the acrylic or methacrylic acid and 15 to 2 wt.- % of (meth)acrylate monomers with a quaternary ammonium group in the alkyl group, and c) an outer coating consisting of a copolymer that is composed of 75 to 95 wt.- % of radically polymerized C1 to C4 alkyl esters of the acrylic or methacrylic acid and 5 to 25 wt.- % of (meth)acrylate monomers with an anionic group in the alkyl group. The inventive product is used for producing a pharmaceutical product that releases the active substance contained therein according to the USP release test, at pH 1.2 during 2 hours and subsequent rebuffering to pH 7.0, by less than 5% after 2.0 hours after start of the test and by 30 to 80% after eight hours after start of the test.
Product Description:
EUDRAGIT® E PO is a fine powder made from EUDRAGIT® E 100. The copolymer complies with monograph “Butylmethacrylat-(2-Dimethylaminoethyl)methacrylat-Mehtylmehtacrylat-Copolymer (1:2:1)” DAB 1998 (Deutsches Arzneibuch, German Pharmacopeia).
EUDRAGIT® E PO is suitable for the manufacture of protective and insulating coatings which dissolve in gastric fluid and of functional layers for transdermal therapy systems (TTS).
Plus a rather disturbing find....
These co-polymer are classified as
Mutagen compounds :o
http://hazard.com/msds/tox/tf/q80/q17.html (http://hazard.com/msds/tox/tf/q80/q17.html)
http://hazard.com/msds/tox/tf/q80/q34.html (http://hazard.com/msds/tox/tf/q80/q34.html)
Plus...another new patent of relevance issued Nov 04, 2003
Patent US6641839 (http://l2.espacenet.com/dips/viewer?PN=US6641839&CY=gb&LG=en&DB=EPD)
Pharmaceutical formulations for preventing drug tolerance